Regenerative pharmacology in the treatment of genetic diseases: The paradigm of muscular dystrophy

Chiara Mozzetta, Giulia Minetti, Pier Lorenzo Puri

Research output: Contribution to journalArticlepeer-review


Current evidence supports the therapeutic potential of pharmacological interventions that counter the progression of genetic disorders by promoting regeneration of the affected organs or tissues. The rationale behind this concept lies on the evidence that targeting key events downstream of the genetic defect can compensate, at least partially, the pathological consequence of the related disease. In this regard, the beneficial effect exerted on animal models of muscular dystrophy by pharmacological strategies that enhance muscle regeneration provides an interesting paradigm. In this review, we describe and discuss the potential targets of pharmacological strategies that promote regeneration of dystrophic muscles and alleviate the consequence of the primary genetic defect. Regenerative pharmacology provides an immediate and suitable therapeutic opportunity to slow down the decline of muscles in the present generation of dystrophic patients, with the perspective to hold them in conditions such that they could benefit of future, more definitive, therapies.

Original languageEnglish
Pages (from-to)701-710
Number of pages10
JournalInternational Journal of Biochemistry and Cell Biology
Issue number4
Publication statusPublished - Apr 2009


  • Chromatin
  • Inflammation
  • Muscular dystrophy
  • Regeneration
  • Signaling pathways

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology


Dive into the research topics of 'Regenerative pharmacology in the treatment of genetic diseases: The paradigm of muscular dystrophy'. Together they form a unique fingerprint.

Cite this